Previous close | 96.57 |
Open | 95.37 |
Bid | 95.04 x 0 |
Ask | 95.32 x 0 |
Day's range | 95.37 - 95.37 |
52-week range | 64.86 - 132.54 |
Volume | |
Avg. volume | 24 |
Market cap | 36.515B |
Beta (5Y monthly) | 1.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -11.56 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
Brad Miller is helping Moderna shift from its reliance on COVID vaccines, with the company hoping to introduce up to 15 new drugs over a five-year period.